Page 50 - 2020_11-Haematologica-web

H. Inaba and C.G. Mullighan
lineage leukemia. Blood. 2018;132(3):264-
276.
92.Fischer U, Forster M, Rinaldi A, et al.
Genomics and drug profiling of fatal TCF3- HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47(9): 1020-1029.
93. Pui CH, Pei D, Raimondi SC, et al. Clinical impact of minimal residual disease in chil- dren with different subtypes of acute lym- phoblastic leukemia treated with Response- Adapted therapy. Leukemia. 2017;31(2):333- 339.
94. O'Connor D, Enshaei A, Bartram J, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36(1):34-43.
95. Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131(12):1350-1359.
96. Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019;6(6):e306- e316.
97. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106.
98. Wolf J, Tang L, Flynn PM, et al. Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia. Clin Infect Dis. 2017;65(11):1790-1798.
99.Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bac- teremia in children with acute leukemia or undergoing hematopoietic stem cell trans- plantation: a randomized clinical trial. JAMA. 2018;320(10):995-1004.
100.Mattano LA Jr, Devidas M, Nachman JB, et al. Effect of alternate-week versus continu- ous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906-915.
101. Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al. Hydrocortisone as an inter- vention for dexamethasone-induced adverse effects in pediatric patients with acute lym- phoblastic leukemia: results of a double- blind, randomized controlled trial. J Clin Oncol. 2016;34(19):2287-2293.
102. Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropa- thy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815-823.
103. Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715-724.
104. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG- asparaginase to reduce asparaginase-associ- ated toxicities: a NOPHO ALL2008 random- ized study. J Clin Oncol. 2019;37(19):1638- 1646.
105.Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051-2061.
106.Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lym- phoblastic leukemia. N Engl J Med.
2016;375(11):1044-1053.
107. Gupta S, Wang C, Raetz EA, et al. Impact of
asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38(17):1897-1905.
108.Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507-514.
109. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA. Universal pre- medication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797.
110. Swanson HD, Panetta JC, Barker PJ, et al. Predicting success of desensitization after pegaspargase allergy. Blood. 2020;135(1):71- 75.
111. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adoles- cents with B-cell precursor acute lym- phoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
112. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T- cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077-2084. Conter V, Valsecchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP cen- tres with AIEOP-BFM protocols: a retrospec- tive analysis. Lancet Haematol. 2016;3(2): e80-86.
114.Raetz EA, Teachey DT. T-cell acute lym- phoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580- 588.
115.Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020 Aug 19 [Epub ahead of print]
121. Vora A, Andreano A, Pui CH, et al. Influence of cranial radiotherapy on outcome in chil- dren with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34(9):919-926.
122. Winick N, Devidas M, Chen S, et al. Impact of initial CSF findings on outcome among patients with National Cancer Institute stan- dard- and high-risk B-cell acute lymphoblas- tic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2017;35(22): 2527-2534.
123.Liu HC, Yeh TC, Hou JY, et al. Triple intrathecal therapy alone with omission of cranial radiation in children with acute lym- phoblastic leukemia. J Clin Oncol. 2014;32(17):1825-1829.
124.Thastrup M, Marquart HV, Levinsen M, et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia. 2020;34(2):336-346.
113.
126.Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-1471.
127.Shen S, Chen X, Cai J, et al. Effect of dasa- tinib versus imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a random- ized clinical trial. JAMA Oncol. 2020;6(3): 358-366.
128.Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with pona- tinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547-1555.
129. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph- like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
130. Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL- class rearrangements. Blood. 2019;134(16): 1351-1355.
131. Seyfried F, Demir S, Horl RL, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signal- ing. Cell Death Dis. 2019;10(8):571.
132.Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL- rearranged leukemia. Blood. 2016;128(10): 1382-1395.
133.Diaz-Flores E, Comeaux EQ, Kim KL, et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79(9):2339-2351.
134. Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lym- phoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285-290.
135.Place AE, Pikman Y, Stevenson KE, et al. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood
116.
117.
118.
119.
Schrappe M, Bleckmann K, Zimmermann M, et al. Reduced-intensity delayed intensi- fication in standard-risk pediatric acute lym- phoblastic leukemia defined by unde- tectable minimal residual disease: results of an international randomized trial (AIEOP- BFM ALL 2000). J Clin Oncol. 2018;36(3): 244-253.
Kato M, Ishimaru S, Seki M, et al. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2017;31(3): 580-584.
Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095-1105. Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children's Oncology Group Study. JAMA Oncol. 2015;1(3):287-295.
120.Landier W, Hageman L, Chen Y, et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Study AALL03N1. J Clin Oncol. 2017;35(15):1730-1736.
125.
Gabelli M, Disaro S, Scarparo P, et al. Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lym- phoblastic leukemia. Leuk Lymphoma. 2019;60(11):2825-2828.
2538
haematologica | 2020; 105(11)